

## Conference call interim report

**Invitation to attend Vitrolife's conference call regarding presentation of the interim report January – June 2021. The presentation will be held in English.**

Time: Thursday 15 July, 2021 at 10.00 a.m. CET.

Registration can preferably be done 10-15 minutes before the conference start time on:

Sweden dial in number: +46 (0)8 566 184 67  
International dial in number: +44 (0) 2071 928338  
Conference name: Vitrolife, conference ID: 1295747

Vitrolife participants:  
Thomas Axelsson, CEO  
Mikael Engblom, CFO

The press release for Vitrolife's interim report will be released at 8.00 CET on the same day.

Before the conference call, presentation material will be available at the company web page, <https://www.vitrolife.com/investors/Presentations/>

A recorded version of the telephone conference will be available for seven days on number +44 (0) 333 300 9785 (International), access code 1295747.

Gothenburg, 30 June 2021  
VITROLIFE AB (publ)

**Contact:**  
Mikael Engblom, CFO, phone +46 (0)31 721 80 14

---

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets products for assisted reproduction. Vitrolife today has approximately 400 employees and the company's products are sold in approximately 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

---

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99.  
E-mail: [info@vitrolife.com](mailto:info@vitrolife.com). Website: [www.vitrolife.com](http://www.vitrolife.com).

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.